全文获取类型
收费全文 | 88601篇 |
免费 | 6942篇 |
国内免费 | 4123篇 |
专业分类
耳鼻咽喉 | 540篇 |
儿科学 | 4560篇 |
妇产科学 | 2309篇 |
基础医学 | 8501篇 |
口腔科学 | 543篇 |
临床医学 | 9890篇 |
内科学 | 11594篇 |
皮肤病学 | 594篇 |
神经病学 | 8259篇 |
特种医学 | 2719篇 |
外国民族医学 | 7篇 |
外科学 | 29113篇 |
综合类 | 10820篇 |
现状与发展 | 18篇 |
一般理论 | 2篇 |
预防医学 | 2096篇 |
眼科学 | 1291篇 |
药学 | 3386篇 |
20篇 | |
中国医学 | 873篇 |
肿瘤学 | 2531篇 |
出版年
2024年 | 135篇 |
2023年 | 1115篇 |
2022年 | 1714篇 |
2021年 | 2770篇 |
2020年 | 2807篇 |
2019年 | 2861篇 |
2018年 | 2990篇 |
2017年 | 2863篇 |
2016年 | 2787篇 |
2015年 | 2793篇 |
2014年 | 4956篇 |
2013年 | 6295篇 |
2012年 | 4286篇 |
2011年 | 5138篇 |
2010年 | 4686篇 |
2009年 | 4692篇 |
2008年 | 4827篇 |
2007年 | 5079篇 |
2006年 | 4994篇 |
2005年 | 4355篇 |
2004年 | 3645篇 |
2003年 | 3185篇 |
2002年 | 2627篇 |
2001年 | 2221篇 |
2000年 | 1894篇 |
1999年 | 1547篇 |
1998年 | 1412篇 |
1997年 | 1299篇 |
1996年 | 1135篇 |
1995年 | 977篇 |
1994年 | 1010篇 |
1993年 | 691篇 |
1992年 | 788篇 |
1991年 | 620篇 |
1990年 | 508篇 |
1989年 | 485篇 |
1988年 | 438篇 |
1987年 | 363篇 |
1986年 | 355篇 |
1985年 | 476篇 |
1984年 | 411篇 |
1983年 | 295篇 |
1982年 | 274篇 |
1981年 | 240篇 |
1980年 | 198篇 |
1979年 | 95篇 |
1978年 | 94篇 |
1977年 | 92篇 |
1976年 | 43篇 |
1975年 | 30篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
《European journal of surgical oncology》2022,48(3):621-631
ObjectivesThe aim of this meta-analysis was to conduct a contemporary systematic review of high quality non-randomised controlled trials to determine the effect of pre-liver transplantation (LT) transarterial chemoembolisation (TACE) on long-term survival and complications of hepatocellular carcinoma (HCC) patients.BackgroundTACE is used as a neoadjuvant therapy to mitigate waitlist drop-out for patients with HCC awaiting LT. Previous studies have conflicting conclusions on the effect of TACE on long-term survival and complications of HCC patients undergoing LT.MethodsCINAHL, Cochrane Controlled Register of Trials, Embase, PubMed, and Web of Science were systematically searched. Baseline characteristics included number of patients outside Milan criteria, tumour diameter, MELD score, and time on the waiting list. Primary outcomes included 3- and 5-year overall and disease-free survival. Secondary outcomes included tumour recurrence, 30-day postoperative mortality, and hepatic artery and biliary complications.ResultsTwenty-one high-quality NRCTs representing 8242 patients were included. Tumour diameter was significantly larger in TACE patients (3.49 cm vs 3.15 cm, P = 0.02) and time on the waiting list was significantly longer in TACE patients (4.87 months vs 3.46 months, P = 0.05), while MELD score was significantly higher in non-TACE patients (10.81 vs 12.35, P = 0.005). All primary and secondary outcomes displayed non-significant differences.ConclusionPatients treated with TACE had similar survival and postoperative outcomes to non-TACE patients, however, they had worse prognostic features compared to non-TACE patients. These findings strongly support the current US and European clinical practice guidelines that neoadjuvant TACE can be used for patients with longer expected waiting list times (specifically >6 months). Randomised controlled trials would be needed to increase the quality of evidence. 相似文献
2.
《Transfusion and apheresis science》2022,61(1):103368
The endothelium is a single-layered structure that responds to physical and chemical signals with various factors it synthesizes. In the early days of its discovery, as the inner wall of the vessels, the endothelium was thought to be a simple barrier that lays on the surface. Over time it is discovered that endothelium maintains body homeostasis with the molecules it synthesizes, despite its simple single-layer structure. It has been accepted as an important organ that contributes to the maintenance of vascular tone, cell adhesion, inflammation, vascular permeability and coagulation. Any imbalance in these physiological and pathological events causes endothelial dysfunction. This can cause many diseases such as atherosclerosis, hypertension, diabetes, or it can occur because of these. Endothelial related disorders may also complicate hematopoietic stem cell transplantation (HSCT), which is used to treat various hematologic and neoplastic diseases. These life-threatening complications include graft-versus-host disease, hepatic veno-occlussive disease, transplant-associated thrombotic microangiopathy and diffuse alveolar hemorrhage. They share a similar pathophysiology involving endothelial cells with different clinical presentations. Therefore, current researche on the issue is putting the endothelium under the spotlight for novel markers and treatment options that should be used to monitor or treat at least some of these complications following HSCT. 相似文献
3.
Mette Nissen Tiina‐Mari Ikheimo Jukka Huttunen Ville Leinonen Henna‐Kaisa Jyrkknen Mikael von und zu Fraunberg 《Neuromodulation》2021,24(1):102-111
ObjectiveSpinal cord stimulation (SCS) is an effective treatment in failed back surgery syndrome (FBSS). We studied the effect of preimplantation opioid use on SCS outcome and the effect of SCS on opioid use during a two-year follow-up period.Materials and methodsThe study cohort included 211 consecutive FBSS patients who underwent an SCS trial from January 1997 to March 2014. Participants were divided into groups, which were as follows: 1) SCS trial only (n = 47), 2) successful SCS (implanted and in use throughout the two-year follow-up period, n = 131), and 3) unsuccessful SCS (implanted but later explanted or revised due to inadequate pain relief, n = 29). Patients who underwent explantation for other reasons (n = 4) were excluded. Opioid purchase data from January 1995 to March 2016 were retrieved from national registries.ResultsHigher preimplantation opioid doses associated with unsuccessful SCS (ROC: AUC = 0.66, p = 0.009), with 35 morphine milligram equivalents (MME)/day as the optimal cutoff value. All opioids were discontinued in 23% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.004). Strong opioids were discontinued in 39% of patients with successful SCS, but in none of the patients with unsuccessful SCS (p = 0.04). Mean opioid dose escalated from 18 ± 4 MME/day to 36 ± 6 MME/day with successful SCS and from 22 ± 8 MME/day to 82 ± 21 MME/day with unsuccessful SCS (p < 0.001).ConclusionsHigher preimplantation opioid doses were associated with SCS failure, suggesting the need for opioid tapering before implantation. With continuous SCS therapy and no explantation or revision due to inadequate pain relief, 39% of FBSS patients discontinued strong opioids, and 23% discontinued all opioids. This indicates that SCS should be considered before detrimental dose escalation. 相似文献
4.
5.
6.
7.
《中国现代医生》2020,58(4):182-184+188
目的 探讨脊柱后路内固定术后硬膜外血肿的预防与护理体会。方法 遵照回顾性分析法选择我院2013年2 月~2018 年2 月纳入的60 例脊柱后路内固定术患者,依照不同理疗方式进行分组。其中30 例给予常规药物治疗作为对照组,另30 例除了常规治疗之外实施综合护理作为研究组,记录两组硬膜外血肿、腰椎术后血肿及颈椎术后血肿发生率,分别在干预前后进行生活质量评分(QOL)调查,出院时发放满意度调查问卷表,对比两组干预结果。结果 研究组血肿发生率为6.67%,明显低于对照组的20.00%(P<0.05)。干预前两组的食欲、精神、睡眠、疼痛及日常生活评分相比差异无统计学意义(P>0.05),干预后研究组的各项评分均高于对照组(P<0.05)。研究组对干预效果的满意度为90.00%,明显高于对照组的76.67%(P<0.05)。结论 护理干预运用于脊柱后路内固定中效果显著,能够有效减少硬膜外血肿的发生率,提升生活质量,促进病情稳定,患者满意度较高,可维持良好医患关系。 相似文献
8.
目的:观察非霍奇金淋巴瘤(non-Hodgkin's lymphoma,NHL)患者自体造血干细胞移植(autologous hematopoietic stem cell transplantation,ASCT)术后应用重组人α-2b干扰素(α-2b IFN)进行早期干预治疗的临床疗效。方法:选取18例行ASCT的NHL患者为研究对象,移植前疾病评估均未达到完全缓解(complete remission,CR),试验组血象恢复后给予IFN 3 000 000 U次/隔日干预治疗,3个月后停用;对照组未行干扰素干预治疗,分析总体疗效及两组对比的生存情况。结果:随访中位时间为34(10~50)个月,患者中位生存时间为37(31~45)个月,3年总体无进展生存(progressive free survival,PFS)、总生存(overall survivial,OS)分别为54.7%、66.8%。ASCT后试验组1年内无疾病复发,2年内复发率为12.5%;对照组1年内复发率为20%,2年内复发率为30%。结论:NHL患者在ASCT后给予重组人α-2b IFN早期干预治疗,患者耐受性好,可能降低移植后早期复发率。 相似文献
9.
Lara Silveira Abdo Aguiar Rita de Cssia Rossini Lismary Aparecida de Forville Mesquita Gerson Dellatorre 《Journal of Cosmetic Dermatology》2019,18(6):1733-1736
Depigmented lesions may occur as postinflammatory sequelae of subacute cutaneous lupus erythematosus (SCLE), leading to great psychosocial impact. A 53‐year‐old male patient presented with post‐SCLE depigmented facial lesions after five years of disease stability. We proposed surgical treatment with melanocyte‐keratinocyte transplantation procedure (MKTP), and after five months the patient achieved 90% repigmentation, without Koebner phenomenon (KP). In theory, KP is a possible complication of MKTP procedure since the preparation of the receptor area involves the use of dermabrasion. In an attempt to avoid it, we suggest to maintain the treatment of the underlying disease and wait for a minimum period of disease stability before the procedure. 相似文献
10.
Jose M. Morales Jose Angel Martinez-Flores Manuel Serrano Maria José Castro Francisco Javier Alfaro Florencio García Miguel Angel Martínez Amado Andrés Esther González Manuel Praga Estela Paz-Artal Antonio Serrano 《Journal of the American Society of Nephrology : JASN》2015,26(3):735-745
In the current immunosuppressive therapy era, vessel thrombosis is the most common cause of early graft loss after renal transplantation. The prevalence of IgA anti–β2-glycoprotein I antibodies (IgA-aB2GPI-ab) in patients on dialysis is elevated (>30%), and these antibodies correlate with mortality and cardiovascular morbidity. To evaluate the effect of IgA-aB2GPI-ab in patients with transplants, we followed all patients transplanted from 2000 to 2002 in the Hospital 12 de Octubre prospectively for 10 years. Presence of IgA-aB2GPI-ab in pretransplant serum was examined retrospectively. Of 269 patients, 89 patients were positive for IgA-aB2GPI-ab (33%; group 1), and the remaining patients were negative (67%; group 2). Graft loss at 6 months post-transplant was significantly higher in group 1 (10 of 89 versus 3 of 180 patients in group 2; P=0.002). The most frequent cause of graft loss was thrombosis of the vessels, which was observed only in group 1 (8 of 10 versus 0 of 3 patients in group 2; P=0.04). Multivariate analysis showed that the presence of IgA-aB2GPI-ab was an independent risk factor for early graft loss (P=0.04) and delayed graft function (P=0.04). There were no significant differences regarding patient survival between the two groups. Graft survival was similar in both groups after 6 months. In conclusion, patients with pretransplant IgA-aB2GPI-ab have a high risk of early graft loss caused by thrombosis and a high risk of delayed graft function. Therefore, pretransplant IgA-aB2GPI-ab may have a detrimental effect on early clinical outcomes after renal transplantation. 相似文献